EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic

Søren Seier iD, Kine Stamp-Larsen, Simon Birk Kjær Jensen, Signe Sørensen Torekov iD, Henrik Gudbergsen iD

Diabetes, Obesity and Metabolism · 2025-12 · 27 (12) · 6979-6987

DOI: 10.1111/dom.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2025. Verfasst von Søren Seier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Weight Reduction Programs, Overweight. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Embla ApS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity. Materials and methods This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence‐based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.

Results

The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: −17.4 to −16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.

Conclusions

Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat‐to‐target approach integrating medical and behavioural obesity management in a digital setting. Trial registration https://osf.io/86kmc/

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesObesityWeight Reduction ProgramsOverweightAnti-Obesity AgentsHumansFemaleMiddle AgedMaleRetrospective StudiesAdultWeight LossTelemedicineDenmarkTreatment OutcomeBody Mass IndexGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1cohort studyobesity carereal‐world evidenceweight management

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Embla ApS, Copenhagen, Denmark.
  • Department of Public Health, Centre for General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Søren Seier, Signe Sørensen Torekov, Henrik Gudbergsen

Förderung

  • Embla ApS

Zitieren

APA

Seier, S., Stamp-Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025). Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic. Diabetes, Obesity and Metabolism, 27(12), 6979-6987. https://doi.org/10.1111/dom.70096

Vancouver

Seier S, Stamp-Larsen K, Jensen SBK, Torekov SS, Gudbergsen H. Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic. Diabetes, Obesity and Metabolism. 2025;27(12):6979-6987. doi:10.1111/dom.70096

BibTeX
@article{Seier2025,
  author = {Seier, Søren and Stamp-Larsen, Kine and Jensen, Simon Birk Kjær and Torekov, Signe Sørensen and Gudbergsen, Henrik},
  title = {Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {6979--6987},
  doi = {10.1111/dom.70096}
}
Kostenlos starten →